VBWG
Data alert

MIRACL: Very early statin therapy not guided by cholesterol levels is beneficial in acute coronary syndromes

Final results of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial have been published and confirm that treatment with atorvastatin 80 mg/d early during an acute coronary syndrome (ACS) reduces the risk of early recurrent events, primarily recurrent symptomatic ischemia during hospitalization.





DA7.ppt

Download DA7.ppt (6 slides - 0.4MB)

Slide 1 Slide 2 Slide 3 Slide 4 Slide 5 Slide 6
Data_Alert.pdf (0.3MB)Data_Alert.pdf (0.3MB)


ACSatorvastatincholesterolcoronaryguidedhospitalizationIschemiaMIRACLMyocardialpublishedstatinsymptomaticsyndromes

Related at vwbg.org

Supplement to The American Journal of Cardiology October 18, 2001 vol. 88 (8A)

A Symposium: Interventions in cardiology: Focus on lipid management in acute and long-term settings

Exciting new data have emerged on the relative roles of medical therapy and percutaneous coronary intervention (PCI) in patients with acute coronary syndromes (ACS).

Core Curriculum

Myocardial Ischemia Redefined: Optimal Care in CAD

View/Download individual slides (90 Slides)
More related